Treatment of early stage chronic hepatitis C virus infection

Francesca Romana Ponziani, Luca Miele, Annalisa Tortora, Manuele Furnari, Giorgia Bodini, Maurizio Pompili, Antonio Gasbarrini, Edoardo Giovanni Giannini

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients’ quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.

Original languageEnglish
Pages (from-to)519-524
Number of pages6
JournalExpert Review of Clinical Pharmacology
Volume11
Issue number5
DOIs
Publication statusPublished - May 4 2018

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Liver Diseases
Therapeutics
Antiviral Agents
Ribavirin
Infection
Reflex
Insulin Resistance
Lymphoma
Appointments and Schedules
Economics
Quality of Life
Viruses
Kidney
Costs and Cost Analysis
Liver

Keywords

  • antiviral treatment
  • extra-hepatic manifestations
  • HCV
  • Low fibrosis
  • outcome
  • pharmaco-economy

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Treatment of early stage chronic hepatitis C virus infection. / Ponziani, Francesca Romana; Miele, Luca; Tortora, Annalisa; Furnari, Manuele; Bodini, Giorgia; Pompili, Maurizio; Gasbarrini, Antonio; Giannini, Edoardo Giovanni.

In: Expert Review of Clinical Pharmacology, Vol. 11, No. 5, 04.05.2018, p. 519-524.

Research output: Contribution to journalReview article

Ponziani, Francesca Romana ; Miele, Luca ; Tortora, Annalisa ; Furnari, Manuele ; Bodini, Giorgia ; Pompili, Maurizio ; Gasbarrini, Antonio ; Giannini, Edoardo Giovanni. / Treatment of early stage chronic hepatitis C virus infection. In: Expert Review of Clinical Pharmacology. 2018 ; Vol. 11, No. 5. pp. 519-524.
@article{dab59af8f0214d7a8cf32f8f417a6cb2,
title = "Treatment of early stage chronic hepatitis C virus infection",
abstract = "Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients’ quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.",
keywords = "antiviral treatment, extra-hepatic manifestations, HCV, Low fibrosis, outcome, pharmaco-economy",
author = "Ponziani, {Francesca Romana} and Luca Miele and Annalisa Tortora and Manuele Furnari and Giorgia Bodini and Maurizio Pompili and Antonio Gasbarrini and Giannini, {Edoardo Giovanni}",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/17512433.2018.1447923",
language = "English",
volume = "11",
pages = "519--524",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "5",

}

TY - JOUR

T1 - Treatment of early stage chronic hepatitis C virus infection

AU - Ponziani, Francesca Romana

AU - Miele, Luca

AU - Tortora, Annalisa

AU - Furnari, Manuele

AU - Bodini, Giorgia

AU - Pompili, Maurizio

AU - Gasbarrini, Antonio

AU - Giannini, Edoardo Giovanni

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients’ quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.

AB - Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients’ quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.

KW - antiviral treatment

KW - extra-hepatic manifestations

KW - HCV

KW - Low fibrosis

KW - outcome

KW - pharmaco-economy

UR - http://www.scopus.com/inward/record.url?scp=85046742715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046742715&partnerID=8YFLogxK

U2 - 10.1080/17512433.2018.1447923

DO - 10.1080/17512433.2018.1447923

M3 - Review article

C2 - 29498556

AN - SCOPUS:85046742715

VL - 11

SP - 519

EP - 524

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 5

ER -